Maxim Group analyst Jason McCarthy raised the price target on Viking Therapeutic (NASDAQ: VKTX) to $28.00 (from $14.00) while maintaining ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst PT Change

Viking Therapeutics (VKTX) Announces Proposed Common Share OfferingSeptember 19, 2018 4:23 PM Viking Therapeutic (VKTX) PT Raised to $28 at SunTrust Robinson HumphreySeptember 18, 2018 3:39 PM Viking Therapeutic (VKTX) PT Raised to 'Street High' $28 at H.C. WainwrightSeptember 18, 2018 11:57 AM Pre-Open Movers 09/18: (VKTX) (NXEO) (TLRY) Higher; (MDGL) (ATHN) (CBRL) Lower (more...)September 18, 2018 9:24 AM Viking Therapeutics (VKTX): VK2809 Phase II Data Tops Madrigal's MGL-3196 - SunTrustSeptember 18, 2018 8:33 AM Viking Therapeutics (VKTX) Climbs 140% After Shares Resume TradingSeptember 18, 2018 7:37 AM Viking Therapeutics (VKTX) to Resume Trading at 7:35 am ETSeptember 18, 2018 7:17 AM Form 8-K Viking Therapeutics, For: Sep 18September 18, 2018 7:11 AM Viking Therapeutics (VKTX) Says Phase 2 Study of VK2809 in Patients with NAFLD and Elevated LDL-Cholesterol Achieved its Primary EndpointSeptember 18, 2018 7:08 AM Viking Therapeutics Announces Positive Top-Line Results from Phase 2 Study of VK2809 in Patients with Non-Alcoholic Fatty Liver Disease (NAFLD) and Elevated LDL-CholesterolSeptember 18, 2018 7:05 AM Viking Therapeutics (VKTX) Halted, News PendingSeptember 18, 2018 7:00 AM